JP2005505521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005505521A5 JP2005505521A5 JP2003516484A JP2003516484A JP2005505521A5 JP 2005505521 A5 JP2005505521 A5 JP 2005505521A5 JP 2003516484 A JP2003516484 A JP 2003516484A JP 2003516484 A JP2003516484 A JP 2003516484A JP 2005505521 A5 JP2005505521 A5 JP 2005505521A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- following formula
- polar
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 31
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 14
- -1 lipid compound Chemical class 0.000 claims 11
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 10
- 239000002502 liposome Substances 0.000 claims 8
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 7
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000016361 genetic disease Diseases 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- 150000001783 ceramides Chemical class 0.000 claims 1
- 229930183167 cerebroside Natural products 0.000 claims 1
- 150000001784 cerebrosides Chemical class 0.000 claims 1
- 150000001982 diacylglycerols Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000002270 gangliosides Chemical class 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 150000002314 glycerols Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000002759 monoacylglycerols Chemical class 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000008103 phosphatidic acids Chemical class 0.000 claims 1
- 150000008105 phosphatidylcholines Chemical class 0.000 claims 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 claims 1
- 150000008106 phosphatidylserines Chemical class 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 150000005846 sugar alcohols Polymers 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 0 **(C1OC1N)C(O)=* Chemical compound **(C1OC1N)C(O)=* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0118517.2A GB0118517D0 (en) | 2001-07-30 | 2001-07-30 | Compound |
| PCT/GB2002/003488 WO2003011252A1 (en) | 2001-07-30 | 2002-07-29 | Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005505521A JP2005505521A (ja) | 2005-02-24 |
| JP2005505521A5 true JP2005505521A5 (enExample) | 2006-01-05 |
Family
ID=9919439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003516484A Pending JP2005505521A (ja) | 2001-07-30 | 2002-07-29 | 極性成分および非極性成分を含む脂質を含む医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040219202A1 (enExample) |
| EP (1) | EP1411898A1 (enExample) |
| JP (1) | JP2005505521A (enExample) |
| CN (1) | CN100457088C (enExample) |
| AU (1) | AU2002317402B2 (enExample) |
| CA (1) | CA2451868A1 (enExample) |
| GB (1) | GB0118517D0 (enExample) |
| RU (1) | RU2294738C2 (enExample) |
| WO (1) | WO2003011252A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO328803B1 (no) * | 2000-03-03 | 2010-05-18 | Thia Medica | Nye fettsyreanaloger |
| AU2003278602C1 (en) * | 2002-06-20 | 2010-08-12 | Pronova Biopharma Norge As | Sulfur-containing phospholipid derivatives |
| DE10236146A1 (de) * | 2002-07-31 | 2004-02-19 | Basf Coatings Ag | Beschichtungsstoff, Verfahren zu seiner Herstellung und seine Verwendung |
| EP1888033B1 (en) * | 2005-06-09 | 2014-02-19 | Meda AB | Method and composition for treating inflammatory disorders |
| CA3144493A1 (en) * | 2006-10-03 | 2008-04-10 | Arbutus Biopharma Corporation | Lipid containing formulations |
| US20110002851A1 (en) * | 2006-11-03 | 2011-01-06 | Medigene Ag | Cationic Colloidal Carriers for Delivery of Active Agents to the Blood-Brain Barrier in the Course of Neuroinflammatory Diseases |
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| EP2105145A1 (en) | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
| AU2009236306B2 (en) * | 2008-04-17 | 2015-04-02 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
| EP3699172A3 (en) | 2008-11-10 | 2020-11-18 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
| RU2394834C1 (ru) * | 2009-06-29 | 2010-07-20 | Учреждение Российской академии наук Институт химической биологии и фундаментальной медицины Сибирского отделения РАН (ИХБФМ СО РАН) | Углеводсодержащие катионные амфифилы, обладающие способностью доставлять нуклеиновые кислоты в клетки млекопитающих |
| US9352042B2 (en) * | 2012-02-24 | 2016-05-31 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| US10286064B2 (en) | 2012-06-15 | 2019-05-14 | Pds Biotechnology Corporation | Cationic lipid vaccine compositions and methods of use |
| BR112015000174A2 (pt) | 2012-07-05 | 2017-06-27 | Taiwan Liposome Co Ltd | método para o tratamento da artrite |
| AU2013317805B2 (en) | 2012-09-21 | 2018-07-26 | Pds Biotechnology Corporation | Improved vaccine compositions and methods of use |
| US9801799B2 (en) | 2013-08-30 | 2017-10-31 | Dalhousia University | Compositions and methods for the removal of tattoos |
| US11612652B2 (en) | 2015-11-13 | 2023-03-28 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
| EP3377043A4 (en) * | 2015-11-20 | 2019-06-26 | The Regents of The University of California | DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN |
| CN110662532A (zh) | 2017-04-03 | 2020-01-07 | 加利福尼亚大学董事会 | 用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs) |
| TW201924722A (zh) | 2017-12-05 | 2019-07-01 | 美商Ｐｄｓ生技公司 | 用於刺激第i型干擾素基因之方法及包含陽離子脂質的組合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0032622B1 (en) * | 1979-12-20 | 1985-08-14 | Dennis Chapman | Polymerisable phospholipids and polymers thereof, methods for their preparation, methods for their use in coating substrates and forming liposomes and the resulting coated substrates and liposome compositions |
| IE912535A1 (en) * | 1990-07-27 | 1992-01-29 | Res Dev Foundation | Liposomes that Provide Thymic Dependent Help to Weak Vaccine¹Antigens |
| ATE222752T1 (de) * | 1993-10-06 | 2002-09-15 | Amgen Inc | Stabile protein-phospholipid zusammensetzungen und verfahren |
| US6187335B1 (en) * | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
| AU753196B2 (en) * | 1998-02-09 | 2002-10-10 | Bracco Research S.A. | Targeted delivery of biologically active media |
| GB9930533D0 (en) * | 1999-12-23 | 2000-02-16 | Mitsubishi Tokyo Pharm Inc | Nucleic acid delivery |
-
2001
- 2001-07-30 GB GBGB0118517.2A patent/GB0118517D0/en not_active Ceased
-
2002
- 2002-07-29 JP JP2003516484A patent/JP2005505521A/ja active Pending
- 2002-07-29 EP EP02745690A patent/EP1411898A1/en not_active Withdrawn
- 2002-07-29 AU AU2002317402A patent/AU2002317402B2/en not_active Ceased
- 2002-07-29 CN CNB028192850A patent/CN100457088C/zh not_active Expired - Fee Related
- 2002-07-29 CA CA002451868A patent/CA2451868A1/en not_active Abandoned
- 2002-07-29 RU RU2004106154/15A patent/RU2294738C2/ru not_active IP Right Cessation
- 2002-07-29 US US10/484,855 patent/US20040219202A1/en not_active Abandoned
- 2002-07-29 WO PCT/GB2002/003488 patent/WO2003011252A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004106154A (ru) | Фармацевтическая композиция, содержащая липиды, которые несут полярный и неполярный фрагмент | |
| US6002029A (en) | Antiviral prodrugs | |
| JP4301571B2 (ja) | 改良された生物学的利用能を有する医薬のプロドラッグ | |
| US6030960A (en) | Method of treating hepatitis virus infections | |
| Eibl | Synthesis of glycerophospholipids | |
| US5677337A (en) | Methods of treatment using pharmaceutically active ceramide-related compositions | |
| US5830430A (en) | Cationic lipids and the use thereof | |
| US5744461A (en) | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use | |
| JP2018184470A5 (enExample) | ||
| JP2002511406A (ja) | 感染症の治療および予防処置のための有機リン化合物の使用 | |
| US4804789A (en) | D-mannite derivatives as starting products for the synthesis of phospholipids | |
| JP2020532546A5 (enExample) | ||
| JP2024023349A5 (enExample) | ||
| JPH0597878A (ja) | エルシル−、ブラシジル−およびネルボニル誘導体、その製造方法、それを含有する腫瘍および原虫によるおよび菌類による疾患に対抗するための医薬および自己免疫疾患および骨髄障害の治療のための医薬およびその医薬の製造方法 | |
| KR20010070962A (ko) | 유기 인 화합물 및 이의 용도 | |
| TW201751B (enExample) | ||
| JP2008519064A5 (enExample) | ||
| AU754862B2 (en) | Use of bisphosphonates for the prevention and treatment of infectious processes | |
| CN1088582C (zh) | 能治疗多种疾病具有层状类脂组分的类脂基载体、其组合物及其应用 | |
| JP2006504635A5 (enExample) | ||
| US20030036533A1 (en) | Phosphorous organic compounds and their use | |
| JP4851946B2 (ja) | 脂質由来ビスホスホン酸 | |
| JP2008528696A5 (enExample) | ||
| JP2007516244A (ja) | 新しいクラスのガンマデルタｔ細胞アクチベーターおよびその使用 | |
| CN1714095A (zh) | 心磷脂分子及合成方法 |